DETERMINATION OF THE EFFECTIVE DOSE OF VIRUS FOR THE DETERMINATION OF VIRUS-NEUTRALIZING ANTIBODIES FROM THE BLOOD SERUM OF ANIMALS VACCINED AGAINST COW-POX
Main Article Content
Authors
K. Zhugunisov
Research institute for biological safety problems, LLP. 080409, Gvardeysky, Republic of Kazakhstan.
B. Myrzakhmetova
Research institute for biological safety problems, LLP. 080409, Gvardeysky, Republic of Kazakhstan.
Moldir Tuyskanova
Research institute for biological safety problems, LLP. 080409, Gvardeysky, Republic of Kazakhstan.
A. Alieva
Research institute for biological safety problems, LLP. 080409, Gvardeysky, Republic of Kazakhstan.
Abstract
Assessment of humoral immunity by serological methods in animals vaccinated against orthopoxviruses often causes difficulties. This indicates that cellular immunity plays a more important role than humoral immunity in orthopoxviruses. This article presents the results of a study aimed at choosing the optimal dose of the virus to determine the neutralizing activity of the serum of animals vaccinated against orthopoxviruses in the neutralization test. According to the results of the study, the neutralization activity of the studied sera at high doses of the virus (ie 100 and 50 TCID50) did not exceed 2 log2, and at lower doses, the neutralization activity was from 4 to 6 log2. A dose of 25 TCID50 was selected as an effective dose among the tested doses of the virus to evaluate post-vaccination humoral immunity of cowpox-vaccinated animals using the neutralization test. This dose contributes to the detection of neutralizing antibody in the sample of the examined serum and its exact quantity, showing high sensitivity and specificity.
Keywords
cowpox, orthopoxvirus, humoral immunity, neutralizing antibody, neutralizing test, optimal dose of virus
Article Details
References
Haller SL, Peng C, McFadden G, Rothenburg S. Poxviruses and the evolution of host range and virulence. Infect Genet Evol. 2014; p.15–40.
Chantrey J, Meyer H, Baxby D, Begon M, Bown KJ, Hazel SM, et al. Cowpox: reservoir hosts and geographic range. Epidemiol Infect. 1999; p. 455–60.
Dubois, M.E.; Slifka, M.K. Retrospective analysis of monkeypox infection. Emerg. Infect. Dis. 2008, 14, 592. [CrossRef] [PubMed].
Balamurugan V., Venkatesan G., Bhanuprakash V., Singh R.K. Camelpox, an emerging orthopox viral disease. Indian J. Virol. 2013;24:295–305. doi: 10.1007/s13337-013-0145-0.
Nemeckova S, Hainz P, Otahal P, Gabriel P, Sroller V, Kutinova L: Early gene expression of vaccinia virus strains replicating (Praha) and non-replicating (modified vaccinia virus strain Ankara, MVA) in mammalian cells. Acta Virol 2001, p. 243-247.
Shelkunova G.A., Shelkunov S.N. 40 let bez ospy. Acta Naturae. 2017; p. 4–12.
Berche P. Life and death of smallpox. Presse Med. 2022 Sep;51(3):104117. doi: 10.1016/j.lpm.2022.104117. Epub 2022 Feb 7. PMID: 35143880.
Strassburg MA. The global eradication of smallpox. Am J Infect Control. 1982 May;10(2):53-9. doi: 10.1016/0196-6553(82)90003-7. PMID: 7044193.
Ninove, L.; Domart, Y.; Vervel, C.; Voinot, C.; Salez, N.; Raoult, D.; Meyer, H.; Capek, I.; Zandotti, C.; Charrel, R.N. Cowpox virus transmission from pet rats to humans, France. Emerg. Infect. Dis. 2009, 15, 781–784. [CrossRef].
Dubois, M.E.; Slifka, M.K. Retrospective analysis of monkeypox infection. Emerg. Infect. Dis. 2008, 14, 592. [CrossRef] [PubMed].
Ducournau, C.; Ferrier-Rembert, A.; Ferraris, O.; Joffre, A.; Favier, A.-L.; Flusin, O.; Van Cauteren, D.; Kecir, K.; Auburtin, B.; Védy, S. Concomitant human infections with 2 cowpox virus strains in related cases, France, 2011. Emerg. Infect. Dis. 2013, 19, 1996. [CrossRef].
Vogel, S.; Sárdy, M.; Glos, K.; Korting, H.C.; Ruzicka, T.; Wollenberg, A. The Munich outbreak of cutaneous cowpox infection: Transmission by infected pet rats. Acta Derm. Venereol. 2012, p.126–131.
Oliveira, J.S.; Figueiredo, P.d.O.; Costa, G.B.; De Assis, F.L.; Drumond, B.P.; Da Fonseca, F.G.; Nogueira, M.L.; Kroon, E.G.; de Souza Trindade, G. Vaccinia virus natural infections in Brazil: The good, the bad, and the ugly. Viruses 2017, 9. [CrossRef] [PubMed].
Vora N.M..; Geleishvili, M.; Hmaladze, E .; Maglakelidze, G .; Navdarashvili, A. Chelovek, Zarazhenie zoonoznym ortopoksvirusom v strane Gruzii. N. Engl. J. Med. 2016, 372, 1223–1230.
Singh, R.K.; Balamurugan, V.; Bhanuprakash, V.; Venkatesan, G.; Hosamani, M. Emergence and reemergence of vaccinia-like viruses: Global scenario and perspectives. Indian J. Virol. 2012, 23, 1–11.
Franco-Luiz, A.P.M.; Fagundes-Pereira, A.; Costa, G.B.; Alves, P.A.; Oliveira, D.B.; Bonjardim, C.A.; Ferreira, P.C.P.; de Souza Trindade, G.; Panei, C.J.; Galosi, C.M. Spread of vaccinia virus to cattle herds, Argentina, 2011. Emerg. Infect. Dis. 2014, 20, 1576.
Franco-Luiz, A.P.M.; Oliveira, D.B.; Pereira, A.F.; Gasparini, M.C.S.; Bonjardim, C.A.; Ferreira, P.C.P.; de Souza Trindade, G.; Puentes, R.; Furtado, A.; Abrahão, J.S. Detection of vaccinia virus in dairy cattle serum samples from 2009, Uruguay. Emerg. Infect. Dis. 2016, 22, 2174.
Usme-Ciro, J.A.; Paredes, A.; Walteros, D.M.; Tolosa-Pérez, E.N.; Laiton-Donato, K.; del Carmen Pinzón, M.; Petersen, B.W.; Gallardo-Romero, N.F.; Li, Y.; Wilkins, K. Detection and molecular characterization of zoonotic poxviruses circulating in the Amazon region of Colombia, 2014. Emerg. Infect. Dis. 2017, 23, 649.
Doshi, R.H.; Guagliardo, S.A.J.; Doty, J.B.; Babeaux, A.D.; Matheny, A.; Burgado, J.; Townsend, M.B.; Morgan, C.N.; Satheshkumar, P.S.; Ndakala, N. Epidemiologic and ecologic investigations of monkeypox, Likouala Department, Republic of the Congo, 2017. Emerg. Infect. Dis. 2019, 25, 273.
Ducournau, C.; Ferrier-Rembert, A.; Ferraris, O.; Joffre, A.; Favier, A.-L.; Flusin, O.; Van Cauteren, D.; Kecir, K.; Auburtin, B.; Védy, S. Concomitant human infections with 2 cowpox virus strains in related cases, France, 2011. Emerg. Infect. Dis. 2013, 19, 1996. [CrossRef].
Vogel, S.; Sárdy, M.; Glos, K.; Korting, H.C.; Ruzicka, T.; Wollenberg, A. The Munich outbreak of cutaneous cowpox infection: Transmission by infected pet rats. Acta Derm. Venereol. 2012, p.126–131.
de Oliveira, J.S.; Figueiredo, P.d.O.; Costa, G.B.; De Assis, F.L.; Drumond, B.P.; Da Fonseca, F.G.; Nogueira, M.L.; Kroon, E.G.; de Souza Trindade, G. Vaccinia virus natural infections in Brazil: The good, the bad, and the ugly. Viruses 2017, 9. [CrossRef] [PubMed].
Venkatesan, G.; Balamurugan, V.; Prabhu, M.; Yogisharadhya, R.; Bora, D.P.; Gandhale, P.N.; Sankar, M.S.; Kulkarni, A.M.; Singh, R.K.; Bhanuprakash, V. Emerging and re-emerging zoonotic buffalopox infection: A severe outbreak in Kolhapur (Maharashtra), India. Vet Ital 2010, p. 439–448.
Mack TM, Noble J, Jr, Thomas DB. A prospective study of serum antibody and protection against smallpox. Am J Trop Med Hyg. (1972) 21:214–8. doi: 10.4269/ajtmh.1972.21.214, PMID: [PubMed] [CrossRef] [Google Scholar]
Gates, I., Olson, V., Smith, S., Patel, N., Damon, I., & Karem, K. (2015). Development of a High-Content Orthopoxvirus Infectivity and Neutralization Assays. PloS one, 10(10), e0138836. Crossref
Zhugunissov K, Mambetaliyev M, Sarsenkulova N, Tabys S, Kenzhebaeva M, Issimov A, Abduraimov Y. Development of an Inactivated Camelpox Vaccine from Attenuated Camelpox Virus Strain: Safety and Protection in Camels. Animals (Basel). 2023 Apr 30;13(9):1513. doi: 10.3390/ani13091513. PMID: 37174551; PMCID: PMC10177572.
Mambetaliyev M, Kilibayev S, Kenzhebaeva M, Sarsenkulova N, Tabys S, Valiyeva A, Muzarap D, Tuyskanova M, Myrzakhmetova B, Rametov N, Sarbassova A, Nurgaziev R, Kerimbayev A, Babiuk S, Zhugunissov K. Field Trials of Live and Inactivated Camelpox Vaccines in Kazakhstan. Vaccines (Basel). 2024 Jun 19;12(6):685. doi: 10.3390/vaccines12060685. PMID: 38932413; PMCID: PMC11209348.
Klasse PJ. Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives. Adv Biol. 2014;2014:157895. doi: 10.1155/2014/157895. Epub 2014 Sep 9. PMID: 27099867; PMCID: PMC4835181.
Bachmann MF, Ecabert B, Kopf M. Influenza virus: a novel method to assess viral and neutralizing antibody titers in vitro. J Immunol Methods. 1999 May 27;225(1-2):105-11. doi: 10.1016/s0022-1759(99)00034-4. PMID: 10365787.
Khalafalla A.I., El Dirdiri G.A. Laboratory and field investigations of a live attenuated and an inactivated camelpox vaccine. J. Camel Pract. Res. 2003;10:191–200.
Abdellatif M.M., Ibrahim A.A., Khalafalla A.I. Development and evaluation of a live attenuated camelpox vaccine from a local field isolate of the virus. Rev. Sci. Tech. 2014;33:831–838. doi: 10.20506/rst.33.3.2321.
Hafez S.M., al-Sukayran A., dela Cruz D., Mazloum K.S., al-Bokmy A.M., al-Mukayel A., Amjad A.M. Development of a live cell culture camelpox vaccine. Vaccine. 1992;10:533–539. doi: 10.1016/0264-410x(92)90353-l.
Manenti A, Molesti E, Maggetti M, Torelli A, Lapini G, Montomoli E. The theory and practice of the viral dose in neutralization assay: Insights on SARS-CoV-2 "doublethink" effect. J Virol Methods. 2021 Nov;297:114261. doi: 10.1016/j.jviromet.2021.114261. Epub 2021 Aug 14. PMID: 34403775; PMCID: PMC8364219.
Manenti A, Solfanelli N, Cantaloni P, Mazzini L, Leonardi M, Benincasa L, Piccini G, Marchi S, Boncioli M, Spertilli Raffaelli C, Tacconi D, Mattiuzzo G, Kistner O, Montomoli E, Trombetta CM. Evaluation of Monkeypox- and Vaccinia virus-neutralizing antibodies in human serum samples after vaccination and natural infection. Front Public Health. 2023 Jun 21;11:1195674. doi: 10.3389/fpubh.2023.1195674. PMID: 37415699; PMCID: PMC10321151.